The recent advances in biotechnology, material science, and precision medicine have further expanded the therapeutic arsenal with cutting-edge strategies ranging from preclinical concepts to clinically available therapies such as platelet-rich plasma (PRP)-based treatment, ECM-based strategies, cold atmospheric plasma (CAP) therapy-based approaches, extracellular vesicles, nanotherapeutics, microRNA (miR)-based strategies, 3D bioprinting and CRISPR/Cas9 technology
Warm vial: Allow vial to reach room temperature (or roll gently between palms) to reduce injection discomfort [6]
Suzuki A, Xiao L, Taketa T, Blum MA, Welsh J, Lin SH, Weston B, Lee JH, Bhutani MS, Rice DC, Mehran RJ, Maru DM, Erasmus JJ, Hofstetter WL, Swisher S , Ajani JA
Figure 4: Time to First Occurrence of Hospitalization for Heart Failure or CV Death in the DECLARE Trial Figure 5: Time to First Occurrence of Hospitalization for Heart Failure in the DECLARE Trial 14.4 Chronic Kidney Disease in Adults The Trial to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD, NCT03036150) was an international, multicenter, randomized, double-blind, placebo-controlled trial in adult patients with chronic kidney disease (CKD) (eGFR between 25 and 75 mL/min/1.73 m2) and albuminuria [urine albumin creatinine ratio (UACR) between 200 and 5000 mg/g] who were receiving standard of care background therapy, including a maximally tolerated, labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB)
